11/21
03:09 am
mbrx
Moleculin Biotech, Inc. (NASDAQ: MBRX) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.
Low
Report
Moleculin Biotech, Inc. (NASDAQ: MBRX) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.
11/18
08:15 am
mbrx
New Findings Show Moleculin's Annamycin Overcomes Resistance to Venetoclax in AML
Medium
Report
New Findings Show Moleculin's Annamycin Overcomes Resistance to Venetoclax in AML
11/14
08:18 am
mbrx
Moleculin Accelerates Planned Unblinded Data Readout for MIRACLE Phase 3 R/R Acute Myeloid Leukemia (AML) Pivotal Trial to H2 2025 [Yahoo! Finance]
High
Report
Moleculin Accelerates Planned Unblinded Data Readout for MIRACLE Phase 3 R/R Acute Myeloid Leukemia (AML) Pivotal Trial to H2 2025 [Yahoo! Finance]
11/14
08:15 am
mbrx
Moleculin Accelerates Planned Unblinded Data Readout for MIRACLE Phase 3 R/R Acute Myeloid Leukemia (AML) Pivotal Trial to H2 2025
High
Report
Moleculin Accelerates Planned Unblinded Data Readout for MIRACLE Phase 3 R/R Acute Myeloid Leukemia (AML) Pivotal Trial to H2 2025
11/13
03:02 am
mbrx
Moleculin Biotech, Inc. (NASDAQ: MBRX) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.
Medium
Report
Moleculin Biotech, Inc. (NASDAQ: MBRX) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.
11/13
02:07 am
mbrx
Moleculin Biotech Reports Financial Highlights and Future Plans [Yahoo! Finance]
Medium
Report
Moleculin Biotech Reports Financial Highlights and Future Plans [Yahoo! Finance]
11/12
02:31 pm
mbrx
Moleculin Biotech, Inc. (NASDAQ: MBRX) had its price target lowered by analysts at Maxim Group from $20.00 to $8.00. They now have a "buy" rating on the stock.
Low
Report
Moleculin Biotech, Inc. (NASDAQ: MBRX) had its price target lowered by analysts at Maxim Group from $20.00 to $8.00. They now have a "buy" rating on the stock.
11/12
08:00 am
mbrx
Moleculin Receives Institutional Review Board Approval for MIRACLE Phase 3 Pivotal Trial of Annamycin in Combination with Cytarabine for the Treatment of R/R Acute Myeloid Leukemia (AML)
Medium
Report
Moleculin Receives Institutional Review Board Approval for MIRACLE Phase 3 Pivotal Trial of Annamycin in Combination with Cytarabine for the Treatment of R/R Acute Myeloid Leukemia (AML)
11/11
07:47 am
mbrx
Moleculin Biotech GAAP EPS of -$2.85 [Seeking Alpha]
High
Report
Moleculin Biotech GAAP EPS of -$2.85 [Seeking Alpha]
11/11
07:09 am
mbrx
Moleculin Reports Third Quarter 2024 Financial Results and Provides Corporate Update [Yahoo! Finance]
Low
Report
Moleculin Reports Third Quarter 2024 Financial Results and Provides Corporate Update [Yahoo! Finance]
11/11
07:05 am
mbrx
Moleculin Reports Third Quarter 2024 Financial Results and Provides Corporate Update
High
Report
Moleculin Reports Third Quarter 2024 Financial Results and Provides Corporate Update
11/5
09:00 am
mbrx
Moleculin to Report Third Quarter 2024 Financial Results on November 8, 2024 and Host Conference Call and Webcast
Medium
Report
Moleculin to Report Third Quarter 2024 Financial Results on November 8, 2024 and Host Conference Call and Webcast
11/5
02:15 am
mbrx
Moleculin Biotech, Inc. (NASDAQ: MBRX) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.
Low
Report
Moleculin Biotech, Inc. (NASDAQ: MBRX) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.
11/4
08:30 am
mbrx
Moleculin Appoints Leading Expert in Pancreatic Cancer to its Scientific Advisory Board to Support Development of Annamycin
Low
Report
Moleculin Appoints Leading Expert in Pancreatic Cancer to its Scientific Advisory Board to Support Development of Annamycin
10/28
02:03 am
mbrx
Moleculin Biotech, Inc. (NASDAQ: MBRX) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.
Low
Report
Moleculin Biotech, Inc. (NASDAQ: MBRX) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.
10/20
02:08 am
mbrx
Moleculin Biotech, Inc. (NASDAQ: MBRX) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.
Low
Report
Moleculin Biotech, Inc. (NASDAQ: MBRX) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.
10/17
08:51 am
mbrx
Transcript from Moleculin's Recent Virtual Acute Myeloid Leukemia KOL Event Now Available [Yahoo! Finance]
Low
Report
Transcript from Moleculin's Recent Virtual Acute Myeloid Leukemia KOL Event Now Available [Yahoo! Finance]
10/17
08:40 am
mbrx
Transcript from Moleculin's Recent Virtual Acute Myeloid Leukemia KOL Event Now Available
Medium
Report
Transcript from Moleculin's Recent Virtual Acute Myeloid Leukemia KOL Event Now Available
10/12
02:05 am
mbrx
Moleculin Biotech, Inc. (NASDAQ: MBRX) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.
Medium
Report
Moleculin Biotech, Inc. (NASDAQ: MBRX) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.
10/7
08:30 am
mbrx
Moleculin to Host Virtual Acute Myeloid Leukemia KOL Event on October 14, 2024
Medium
Report
Moleculin to Host Virtual Acute Myeloid Leukemia KOL Event on October 14, 2024
10/4
09:00 am
mbrx
Moleculin to Present at Two Upcoming Investor Conferences
Medium
Report
Moleculin to Present at Two Upcoming Investor Conferences
10/4
02:12 am
mbrx
Moleculin Biotech, Inc. (NASDAQ: MBRX) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.
Medium
Report
Moleculin Biotech, Inc. (NASDAQ: MBRX) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.
10/4
02:12 am
mbrx
Moleculin Biotech, Inc. (NASDAQ: MBRX) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.
Medium
Report
Moleculin Biotech, Inc. (NASDAQ: MBRX) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.
9/26
02:11 am
mbrx
Moleculin Biotech, Inc. (NASDAQ: MBRX) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.
Low
Report
Moleculin Biotech, Inc. (NASDAQ: MBRX) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.
9/23
08:00 am
mbrx
Moleculin Announces Positive In Vivo Efficacy Data of Annamycin in Orthotopic and Experimental Lung Metastatic Models of Sarcoma
Medium
Report
Moleculin Announces Positive In Vivo Efficacy Data of Annamycin in Orthotopic and Experimental Lung Metastatic Models of Sarcoma